The relationship between prior auto-HCT and increased risk of ICANS is likely very complex and may involve a combination of disease- and treatment-related factors (eg, prior bendamustine use had a nonsignificant trend with increased ICANS), as well as immunological considerations.
← all excerpts
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.
1
—
—